Loading company
CRISPR Therapeutics AG
CRSP · Nasdaq · ·
Next earnings: November 9, 2026
$56.03+3.6%Sep 29 close
- 1M
- -2.9%
- 6M
- +26.4%
- 1Y
- -13.5%
- 5Y
- -52.2%
CRSP · Nasdaq · ·
Next earnings: November 9, 2026
$56.03+3.6%Sep 29 close
CRISPR Therapeutics AG is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $10.2M | $892K | +1,041.37% |
| Profit | -$91.2M | -$208.5M | +56.29% |
| Profit per share | -$0.94 | -$2.40 | +60.83% |
| Free Cash Flow | -$84.1M | -$114M | +26.19% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Vivo Liver Editing Programs CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase editing technology. The Company's in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company's disclosed development candidates also include CTX460, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from CRISPR Therapeutics AG’s Item 2.02 8-K filed August 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
CRISPR Therapeutics AG has no earnings call transcript available.